Synaffix B.V. announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors
Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert,
the former Chief Scientific Officer of ImmunoGen, Inc.
Synaffix Launches toxSYN™, a New Platform of ADC Payloads
AMSTERDAM, NETHERLANDS – December 6, 2017 – Synaffix BV, a biotechnology company that has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates (ADCs), today announced the launch of a new platform of highly potent cytotoxic ADC payloads that will be integrated into its existing ADC platform. With this expansion, Synaffix becomes a one-stop provider for technologies required to rapidly translate antibodies into proprietary ADC products.
ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement
Synaffix BV announced today that ADC
Therapeutics has triggered a second target-specific license under their Commercial License
Agreement dated October 2016, to develop an antibody-drug conjugate (ADC) using Synaffix’s
proprietary site-specific antibody-drug conjugation technology. As part of the original
agreement, ADC Therapeutics retains an option to take a limited number of additional singletarget
licenses for their potential future programs.
Synaffix Awarded "Runner Up" Postion for Best Platform ADc Technology
World ADC is pleased to announce the finalists in the 4th Annual World ADC Awards. The World ADC Awards showcase the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry. Across 9 categories the Awards will recognise the extraordinary endeavours, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.
New Data Demonstrate Significant Expansion of Therapeutic Index vs Cysteine-Engineered ADCs
AMSTERDAM, NETHERLANDS – February 20, 2017 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology, today announced a new set of head-to-head data, that demonstrates the potential of its technology to significantly expand the therapeutic index vs cysteine-engineered ADCs.
Key Synaffix Patent Covering Glycan-Conjugated ADC Process Granted in the United States
AMSTERDAM, NETHERLANDS – December 8, 2016 – Synaffix BV, a biotechnology
company exclusively focused on the development of industry-leading antibody-drug
conjugate (ADC) technology platforms, today announced that a key patent that
encompasses the entire GlycoConnect™ process used to prepare glycan-conjugated ADCs
has been granted in the US (US 9,504,758 B2), further strengthening its IP portfolio.
Synaffix Enters into a Commercial License Agreement with ADC Therapeutics
AMSTERDAM, NETHERLANDS – October 20, 2016 – Synaffix BV announced today it has entered
into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™
and HydraSpace™ site-specific antibody-drug conjugate technologies.
Under the terms of the agreement, ADC Therapeutics has been granted a single-target license
for one of its preclinical programs and has also been granted an option to take a limited number
of additional single-target licenses for potential future programs.
all related news
Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and Expands Its Scientific Advisory Board
AMSTERDAM, THE NETHERLANDS — Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced the completion of a new set of preclinical studies that further supports the potential for its technology to enable safer and more effective targeted cancer therapeutics. The data obtained in these studies capture the outcomes from its latest R&D efforts demonstrating that Synaffix platform technologies, GlycoConnect™ and HydraSpace™, generate ADCs with significantly improved therapeutic index when compared directly to Kadcyla® and Adcetris®, the two FDA-approved ADCs for the treatment of Her2-positive breast cancer and multiple lymphoma indications, respectively.